OncoPharm

Nivolumab-AVD is finally approved for Hodgkin Lymphoma, and primary G-CSF prophylaxis is recommended (?) in the PI.

Also, brief NOLA preview for HOPA attendees. The Big Easy Debate: sazerac or hurricane?

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Tazemetostat is withdrawn from the market due to a risk of secondary malignancies.

RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it does, but does that make a difference?

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Lots of FDA approval updates to discuss from the past few weeks:
-Zongertinib gets approved in 1st line setting for ERBB2 TKD mutated metastatic NSLCLC
-Encorafenib approval with cetuximab + FOLFOX
-Teclistamab + Daratumumab approved in 2nd line setting for r/r multiple myeloma
-Acalabrutinib + venetoclax (but NOT acalabrutinib + venetoclax + obinutuzumab) is approved for CLL

Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

This week discuss BR.31 trial of adjuvant durvalumab in NSCLC and put it into the context of the positive studies with atezolizumab and pembrolizumab. We also highlight 2 notable presentations at ASCO GU 2026 on perioperative enfortumab vedotin + pembrolizumab in cisplatin-eligible patients with resectable bladder cancer (KEYNOTE-B15) and advjuant pembrolizumab + belzutifan in RCC (LITESPARK-022)

Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

An exciting new drug, rezatapopt, may be effective in restoring p53 activity in cancers - a possible major therapeutic breakthrough. Can colchicine treat pyrexia from tremetinib & dabrafenib use? This case series says - maybe: https://doi.org/10.1007/s00520-019-4654-2

Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm